Molap (Lacidipine)

Lacidipine, the active ingredient in Molap, is a calcium channel blocker presented as an oral tablet for oral use. It is prescribed to lower elevated blood pressure in adults with hypertension. GNH USA supplies Molap as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacidipine is used to manage conditions within the hypertension disease family.

Hypertension: reduces systolic and diastolic blood pressure in patients with high blood pressure. Essential hypertension: provides sustained blood pressure control in primary hypertension. High blood pressure: helps achieve target blood pressure levels as part of antihypertensive therapy.

Lacidipine may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate pain often occurring after dose initiation. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: sensation of light‑headedness, especially when standing. - Tachycardia: increased heart rate in some patients. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Angioedema: swelling of face, lips, tongue, or throat. - Myocardial infarction: rare occurrence of heart attack. - Liver dysfunction: abnormal liver enzymes indicating hepatic injury.

Before initiating therapy, consider the following precautions.

Monitor blood pressure: ensure adequate control without excessive lowering. Use cautiously in hepatic impairment: adjust therapy if liver function is compromised. Avoid abrupt discontinuation: taper dose to prevent rebound hypertension. Exercise caution in elderly patients: increased sensitivity to blood pressure changes. Avoid concomitant strong CYP3A4 inhibitors: may raise lacidipine levels. Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Lacidipine can interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentration. - Grapefruit juice: can elevate drug levels and risk of hypotension. - Other potent antihypertensives (e.g., ACE inhibitors, ARBs) when combined may cause excessive blood pressure drop.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Diuretics: additive effect on blood pressure and electrolyte balance. - NSAIDs: may blunt antihypertensive response. - Beta‑blockers: monitor for combined bradycardia or hypotension.